250 related articles for article (PubMed ID: 16087778)
21. Rasagiline.
Schapira A; Bate G; Kirkpatrick P
Nat Rev Drug Discov; 2005 Aug; 4(8):625-6. PubMed ID: 16106586
[No Abstract] [Full Text] [Related]
22. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
Marconi S; Zwingers T
Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1879-82. PubMed ID: 25010617
[TBL] [Abstract][Full Text] [Related]
23. The fabulous neuroprotection of selegiline: memoir and prospectus.
Landau WM
J Child Neurol; 2010 Oct; 25(10):1302-4. PubMed ID: 20940135
[No Abstract] [Full Text] [Related]
24. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
Jost WH; Friede M; Schnitker J
Eur Rev Med Pharmacol Sci; 2014 Nov; 18(22):3349. PubMed ID: 25491607
[No Abstract] [Full Text] [Related]
25. [Rasagiline in motor fluctuations].
Miletzki A
Fortschr Neurol Psychiatr; 2005 Sep; 73(9):488. PubMed ID: 16217881
[No Abstract] [Full Text] [Related]
26. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119
[No Abstract] [Full Text] [Related]
27. Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease.
Sanz E; Romera M; Bellik L; Marco JI; Unzeta M
Med Sci Monit; 2004 Dec; 10(12):BR477-84. PubMed ID: 15567979
[TBL] [Abstract][Full Text] [Related]
28. [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl].
Pálfi M; Szökó E; Kálmán M
Orv Hetil; 2006 Jul; 147(27):1251-7. PubMed ID: 16927880
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in Parkinson's disease.
Vécsei L
Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
[No Abstract] [Full Text] [Related]
30. Selegiline in Parkinson's disease.
Calne DB
BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
[No Abstract] [Full Text] [Related]
31. New drug treatment for Parkinson's disease.
FDA Consum; 2006; 40(4):7. PubMed ID: 17245831
[No Abstract] [Full Text] [Related]
32. MAO-B inhibitors for the treatment of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
[No Abstract] [Full Text] [Related]
33. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
34. Free-radical toxicity and antioxidant medications in Parkinson's disease.
Ciccone CD
Phys Ther; 1998 Mar; 78(3):313-9. PubMed ID: 9520976
[No Abstract] [Full Text] [Related]
35. Selegiline, pregnancy, and Parkinson's disease.
Kupsch A; Oertel WH
Mov Disord; 1998 Jan; 13(1):175-6. PubMed ID: 9452347
[No Abstract] [Full Text] [Related]
36. The multiple actions of selegiline.
Ebadi M; Sharma S; Shavali S; Sangchot P; Brekke L
Proc West Pharmacol Soc; 2002; 45():39-41. PubMed ID: 12434521
[No Abstract] [Full Text] [Related]
37. Rasagiline. Teva Pharmaceutical.
Kupsch A
Curr Opin Investig Drugs; 2002 May; 3(5):794-7. PubMed ID: 12090555
[TBL] [Abstract][Full Text] [Related]
38. Rasagiline -- is there a place for this drug in managing Parkinson's disease?
Sharma JC
Int J Clin Pract; 2006 Feb; 60(2):132-3. PubMed ID: 16451281
[No Abstract] [Full Text] [Related]
39. Deprenyl--past and future. Proceedings of a symposium. Lake Starnberg, Bavaria, 1995.
J Neural Transm Suppl; 1996; 48():1-112. PubMed ID: 9102455
[No Abstract] [Full Text] [Related]
40. The delayed-start study in Parkinson disease: can't satisfy everyone.
Olanow CW; Rascol O
Neurology; 2010 Apr; 74(14):1149-50. PubMed ID: 20368635
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
